Announced Sat, 27 Jun · 10:35 IST
US FDA completes inspection at subsidiary Auroactive Pharma with 2 observations
Business Updates View source PDF
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.2%1-day move
₹1554.60
prior close
₹1555.20
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.7+0.8+0.6+1.8+1.2-0.3+0.5+4.0+2.6+0.2+0.3———
Up moveDown movePending
AI summary
US FDA inspected Aurobindo Pharma's wholly owned subsidiary Auroactive Pharma Private Limited, which makes APIs and formulation intermediates at its Srikakulam, Andhra Pradesh facility, from June 22 to June 26, 2026. The inspection concluded with 2 observations. The company says it will respond within the stipulated time and that there is no impact on financials or operations. Auroactive Pharma is a wholly owned subsidiary of Aurobindo Pharma.
Likely market impact
Minor FDA observations with no stated financial or operational impact. Markets typically view 2 observations as routine, but response outcome matters.